Novo Nordisk announced today the issuance of a letter to health care providers, as required by a Risk Evaluation and Mitigation Strategy, reminding them of important safety information associated with liraglutide injection. According to the FDA, a recent evaluation showed that some primary care providers are unaware of the serious risks associated with liraglutide (Victoza).
